HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Cytotoxic effect of topoisomerase II inhibitors against adriamycin- and etoposide-resistant small cell lung cancer sublines].

Abstract
Using reverse transcription polymerase chain reaction, we determined mRNA expression of topoisomerase (topo) II alpha and beta in adriamycin- and etoposide-resistant small cell lung cancer sublines, SBC-3/ADM 100 and SBC-3/ETP. The expression of topo II alpha mRNA decreased substantially in SBC-3/ADM 100 and SBC-3/ETP as compared with the parent cell line, SBC-3; 0.71-fold in the former and 0.38-fold in the latter. Similarly, that of topo II beta mRNA decreased to an extent of 0.68-fold in SBC-3/ADM 100 and 0.28-fold in SBC-3/ETP as compared with the parent cell line. SBC-3/ADM 100 and SBC-3/ETP were highly resistant to topo II inhibitors such as daunorubicin, epirubicin, pirarubicin, mitoxantrone, and teniposide. However, SBC-3/ADM 100 showed a less resistance to aclarubicin, and SBC-3/ETP was as sensitive to the drug as was in the parent cell line. The resistance to topo II inhibitors excluding for aclarubicin might be partially explained by the decreased expression of topo II alpha and beta mRNA.
AuthorsN Takigawa, T Ohnoshi, H Ueoka, T Yonei, K Kiura, M Tabata, T Kodani, H Kamei, Y Segawa, T Shibayama
JournalGan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 20 Issue 7 Pg. 929-35 (May 1993) ISSN: 0385-0684 [Print] Japan
PMID8387762 (Publication Type: English Abstract, Journal Article)
Chemical References
  • RNA, Messenger
  • Topoisomerase II Inhibitors
  • Etoposide
  • Doxorubicin
Topics
  • Carcinoma, Small Cell (genetics, pathology)
  • Doxorubicin (pharmacology)
  • Drug Resistance
  • Etoposide (pharmacology)
  • Humans
  • Lung Neoplasms (genetics, pathology)
  • Polymerase Chain Reaction
  • RNA, Messenger (analysis)
  • Topoisomerase II Inhibitors
  • Tumor Cells, Cultured (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: